Article thumbnail

Identification and Replication of Loci Involved in Camptothecin-Induced Cytotoxicity Using CEPH Pedigrees

By Venita Gresham Watson, Alison Motsinger-Reif, Nicholas E. Hardison, Eric J. Peters, Tammy M. Havener, Lorraine Everitt, James Todd Auman, Daniel L. Comins and Howard L. McLeod


To date, the Centre d'Etude Polymorphism Humain (CEPH) cell line model has only been used as a pharmacogenomic tool to evaluate which genes are responsible for the disparity in response to a single drug. The purpose of this study was demonstrate the model's ability to establish a specific pattern of quantitative trait loci (QTL) related to a shared mechanism for multiple structurally related drugs, the camptothecins, which are Topoisomerase 1 inhibitors. A simultaneous screen of six camptothecin analogues for in vitro sensitivity in the CEPH cell lines resulted in cytotoxicity profiles and orders of potency which were in agreement with the literature. For all camptothecins studied, heritability estimates for cytotoxic response averaged 23.1±2.6%. Nonparametric linkage analysis was used to identify a relationship between genetic markers and response to the camptothecins. Ten QTLs on chromosomes 1, 3, 5, 6, 11, 12, 16 and 20 were identified as shared by all six camptothecin analogues. In a separate validation experiment, nine of the ten QTLs were replicated at the significant and suggestive levels using three additional camptothecin analogues. To further refine this list of QTLs, another validation study was undertaken and seven of the nine QTLs were independently replicated for all nine camptothecin analogues. This is the first study using the CEPH cell lines that demonstrates that a specific pattern of QTLs could be established for a class of drugs which share a mechanism of action. Moreover, it is the first study to report replication of linkage results for drug-induced cytotoxicity using this model. The QTLs, which have been identified as shared by all camptothecins and replicated across multiple datasets, are of considerable interest; they harbor genes related to the shared mechanism of action for the camptothecins, which are responsible for variation in response

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1993). A first-generation physical map of the human genome.
  2. (2000). A gene expression database for the molecular pharmacology of cancer.
  3. (2003). Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity.
  4. (2009). Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity.
  5. (2002). Camptothecins: a review of their chemotherapeutic potential.
  6. (2008). Cancer proliferation gene discovery through functional genomics.
  7. (1990). Centre d’etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome.
  8. (2005). Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
  9. (1994). Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
  10. (1998). Comprehensive human genetic maps: individual and sex-specific variation in recombination.
  11. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery.
  12. (2006). Exploring the mode-of-action of bioactive drugs by chemical-genetic profiling in yeast.
  13. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.
  14. (2008). Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines.
  15. (2009). Genetic analysis of radiation-induced changes in human gene expression.
  16. (1995). Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results.
  17. (2002). Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.
  18. (2005). Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae.
  19. (2004). Genomewide discovery of loci influencing chemotherapy cytotoxicity.
  20. (2009). Genomics: Applications in mechanism elucidation.
  21. (2004). Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
  22. (2010). How accurate are cancer cell lines?
  23. (2003). Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
  24. (2006). In silico pharmacogenetics of warfarin metabolism.
  25. (2007). Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis.
  26. (2007). Mapping genes that contribute to daunorubicin-induced cytotoxicity.
  27. (2006). Mechanisms of Cellular Resistance to Camptothecins. In: Curr Med Chem Anticancer Agents. Bentham Science Publishers Ltd.
  28. (2000). NK1 (substance P) receptor antagonists - why are they not analgesic in humans?
  29. (2009). Pharmacogenomic discovery using cell-based models.
  30. (2008). Profiling essential genes in human mammary cells by multiplex RNAi screening.
  31. (2005). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, Available: http:// QTLs Linked to Variable Response to Camptothecins PLoS
  32. (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.
  33. (2006). Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.
  34. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.
  35. (2008). Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors.
  36. (2008). Tefferi A
  37. (2006). Topoisomerase I inhibitors: camptothecins and beyond.
  38. (2002). Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
  39. (2004). Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action.